Publications by authors named "N Ettahar"

In June 2022, a 73-year-old man with a history of laryngeal and esophageal carcinoma was admitted to the emergency unit with sudden fever, confusion, and general condition deterioration. Initial assessments showed a fever of 38.5 °C, elevated C-reactive protein (CRP) at 209 mg/L, and a neutrophil count of 10.

View Article and Find Full Text PDF
Article Synopsis
  • The study examines current practices with long half-life lipoglycopeptides (LGPs), particularly oritavancin, and how they're mainly used off-label for bone and joint infections (BJIs) and infective endocarditis despite being approved only for skin and soft tissue infections (SSTIs).
  • Oritavancin, along with dalbavancin, is notable for its one-time dosing, with oritavancin potentially offering advantages for shorter treatment durations (less than 2 weeks) and various infections like urinary tract infections and catheter-related infections.
  • The findings suggest that LGPs, such as oritavancin, are changing treatment approaches for acute bacterial infections and may
View Article and Find Full Text PDF

Background: The intravenous form of fosfomycin, a bactericide antibiotic used to treat multiresistant bacterial infections is little prescribed. The most common reported adverse effects are hypokaliemia and hypernatremia. We describe a case of agranulocytosis, a rarely described side effect that may be fatal.

View Article and Find Full Text PDF

Oseltamivir is a neuraminidase inhibitor approved for the prevention and treatment of influenza. Few haematological side effects have been reported with oseltamivir. We report herein the case of an unexpected platelet increase in a 46-year-old woman with idiopathic thrombocytopenia (ITP) treated with oseltamivir for influenza.

View Article and Find Full Text PDF

Introduction: In treatment of prosthetic vascular graft infection (PVGI), appropriate antimicrobial treatment is crucial for controlling the septic process and preventing re-infection of the new graft. Glycopeptides are the mainstay of treatment for device-related infections by methicillin-resistant Staphylococcus aureus strains, but with some limitations, especially concerning vancomycin-intermediate and glycopeptide-intermediate S. aureus.

View Article and Find Full Text PDF